Search Results
Your search for it matches 15474 pages
Showing 4451 - 4500Expert Point of View: Basem M. William, MD, MRCP (UK), FACP, and Caron Jacobson, MD
Basem M. William, MD, MRCP (UK), FACP, Director of the T-Cell Lymphoma Program and a member of the Blood and Marrow Transplant Program at The Ohio State University Comprehensive Cancer Center, Columbus, said many of the new-generation bispecific antibodies are “highly promising.” He said they...
Bispecific Antibodies Poised to Impact Treatment of Lymphoma and Other Blood Cancers
Studies of second-generation bispecific antibodies were among the highlights of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition. The bispecific T-cell engager blinatumomab was the first such agent to be approved by the U.S. Food and Drug Administration (FDA) in...
Chemotherapy-Free Approaches in Follicular and Mantle Cell Lymphomas
As chemotherapy and chemoimmunotherapy regimens reach their maximal impact in follicular lymphoma and mantle cell lymphoma, clinicians are turning to chemotherapy-free approaches to achieve better control, less toxicity, and (hopefully) a cure. During the ASCO20 Virtual Education Program, Sonali...
Role of Rituximab in Treatment of Children and Adolescents With Mature B-Cell Non-Hodgkin Lymphoma
The European Intergroup for Childhood Non-Hodgkin Lymphoma/Children’s Oncology Group (EICNHL/COG) recently reported a significant improvement in event-free survival among children and adolescents (aged 6 months to 18 years) with high-risk mature B-cell non-Hodgkin lymphoma (B-NHL) following the...
Optimizing the Treatment of Adults With Acute Lymphoblastic Leukemia
In the treatment of adults with acute lymphoblastic leukemia (ALL), use of newer antibodies and de-intensification of chemotherapy have greatly improved outcomes, according to Hagop Kantarjian, MD, FASCO, who has been very involved in much of the research in ALL treatment. Dr. Kantarjian, Professor ...
Screening Younger Women for Variants Linked to Breast and Ovarian Cancers May Be Cost-Effective
Population-wide screening for genetic variants linked to hereditary breast and ovarian cancers may be cost-effective in women between the ages of 20 and 35, according to a study published by Guzauskas et al in JAMA Network Open. However, screening for older women was not cost-effective, the...
State of Lung Cancer Report Finds People of Color Face Greater Burden, Worse Lung Cancer Outcomes in the United States
People of color diagnosed with lung cancer face worse outcomes compared to White Americans, according to the American Lung Association’s third annual State of Lung Cancer report. The 2020 State of Lung Cancer report tracks the toll of lung cancer by state, and for the first time, this year’s report ...
Study Finds the Lung Microbiome May Affect Tumor Progression and Prognosis in Patients With Lung Cancer
A new study by Tsay et al sheds light on the role the lung microbiome may play in lung cancer pathogenesis and prognosis. According to the study’s findings, enrichment of the lungs with oral commensal microbes was associated with advanced-stage disease, worse prognosis, and tumor progression....
FDA Issues Emergency Use Authorization for First COVID-19 Test for Self-Testing at Home
On November 17, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the first COVID-19 diagnostic test for self-testing at home. The Lucira COVID-19 All-In-One Test Kit, which provides rapid results, is a molecular (real-time loop mediated amplification...
Paclitaxel Plus Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer: Long-Term Follow-up and Genomic Analysis
In a 7-year follow-up of the phase III CALGB 40601/Alliance neoadjuvant trial reported in the Journal of Clinical Oncology, Fernandez-Martinez et al found that paclitaxel combined with trastuzumab/lapatinib was associated with improved survival outcomes vs paclitaxel/trastuzumab in women with...
Cancer Deaths Linked to 4 Million Potential Years of Life Lost in 2017
Deaths from cancer accounted for more than 4 million potential years of life lost in 2017, according to a study published by Minkyo Song, MD, PhD, and colleagues in Cancer Epidemiology, Biomarkers & Prevention. While the cancer types with the highest death rates per capita accounted for the...
Immune-Related Adverse Events and Survival Outcomes in NSCLC
This week, we’re focusing on lung cancer—first, with a report on how therapy-related adverse events experienced by patients with lung cancer treated with immunotherapy may help to predict survival outcomes; and second, with a video about disparities in certain populations when it comes to lung...
Virtual Mind-Body Services for Patients With Cancer During the COVID-19 Pandemic
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Jun J. Mao, MD, MSCE, and Jyothirmai Gubili, MS, focus on the role of virtual...
Survey Finds Patients With Cancer May Be Less Likely to Enroll in Clinical Trials During the COVID-19 Pandemic
A portion of patients with cancer may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic. According to a report published as a research letter by Mark E. Fleury, PhD, and colleagues in JAMA Oncology, nearly one in five patients with cancer surveyed said the...
Is Maintenance Treatment With Olaparib for BRCA-Mutated Pancreatic Cancer Cost-Effective?
Studies have shown that utilizing a PARP inhibitor in the management of patients with metastatic pancreatic cancer and BRCA1/2 mutation is clinically beneficial. New research published by Wu et al in JNCCN—Journal of the National Comprehensive Cancer Network sought to determine whether such...
Genetic Variants Linked to Bevacizumab-Induced Adverse Effects
Two common genetic variants appear to be linked to toxicity induced by bevacizumab, researchers reported at the 32nd European Organisation for Research and Treatment of Cancer (EORTC)–National Cancer Institute (NCI)–American Association for Cancer Research (AACR) Symposium on Molecular Targets and...
Expert Point of View: Therese Marie Mulvey, MD, FASCO
Therese Marie Mulvey, MD, FASCO, Director of Quality Safety and Value at the Massachusetts General Hospital North Shore Cancer Center, Boston, told The ASCO Post that this “provocative and elegant” study underscores the importance of listening to patients. “Baseline patient-reported symptoms are...
Ask Patients With Advanced Cancer About Fatigue: The Answer May Reveal Survival Odds
Fatigue could be an important baseline stratification factor for cancer treatment, according to data presented during the 2020 ASCO Quality Care Symposium.1 An analysis of four SWOG treatment trials has found an association between patient fatigue and outcomes in advanced cancer. Data from the...
Study Finds State-Level Lung Cancer Screening Rates Not Aligned With Lung Cancer Burden in the United States
A new study published by Stacey A. Fedewa, PhD, and colleagues in JNCI: Journal of the National Cancer Institute found that state-level lung cancer screening rates were not aligned with the national lung cancer burden. The report provides the first population-based state-level screening data for...
Comanagement of Induction Therapy for Acute Promyelocytic Leukemia by Experts and Community Practices
In a study reported in JCO Oncology Practice, Anand P. Jillella, MD, and colleagues found that physician education on the main causes of death during induction treatment for acute promyelocytic leukemia (APL)—and comanagement of cases with expert physicians—resulted in a low early mortality rate...
Closing the Gap in Integrative Oncology Education
Launched in 2018 at the University of Michigan Medical School in Ann Arbor, the Integrative Oncology Scholars Program has trained 50 oncology professionals in evidence-based complementary therapies in the treatment of patients with cancer. Another 50 trainees are expected to complete the program by ...
Medicaid Expansion Associated With Decreased Mortality in Patients With Newly Diagnosed Breast, Colorectal, and Lung Cancers
In states that have expanded Medicaid availability as part of the Affordable Care Act (ACA), mortality rates for three major types of cancer are significantly lower than in states that have not expanded their Medicaid, according to findings from a new study published by Miranda B. Lam, MD, MBA, and ...
rhG-CSF and Decitabine to Reduce Risk of Relapse in Patients With AML After Stem Cell Transplant
In a Chinese phase II trial reported in the Journal of Clinical Oncology, Gao et al found that prophylactic recombinant human granulocyte colony-stimulating factor (rhG-CSF) and minimal-dose decitabine reduced the risk of relapse vs no intervention among patients with high-risk, minimal residual...
Hospital Outpatient Payment Proposal Has Potential to Undermine Patient Access to Cancer Care
In a comment letter to the Centers for Medicare & Medicaid Services (CMS), the Association for Clinical Oncology (ASCO) expressed significant concerns that provisions in the 2021 Hospital Outpatient Prospective Payment System (HOPPS) proposed rule have the potential to undermine access to...
Your Stories: ‘Being Your Own Advocate’
Kimberly Irvine was used to taking care of the people she loved. Conquering breast cancer—twice—forced the young mom to learn how to take care of herself in a whole new way. In the Your Stories episode “Being Your Own Advocate,” she shares with fellow philanthropist Riccardo Braglia, Board Member, ...
COVID-19’s Impact on Cancer Care Around the World: Perspectives From the ASCO International Affairs Committee
As the world continues to respond to the COVID-19 pandemic, ASCO is committed to providing the most current information and resources to its members and the larger oncology community to help ensure that patients with cancer receive high-quality care. Here, members of the ASCO International Affairs...
Stereo X-Ray of Stomach Cancer
The text and photograph here are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, The X-Ray Era 1901–1915 by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. Photograph courtesy of Stanley B. Burns, MD, and The Burns Archive. A few...
My Age May Have Been a Barrier to Timely Diagnosis of Glioblastoma Multiforme
I think my age and apparent good health contributed to a delay in my diagnosis of glioblastoma multiforme. The first symptom I had of the cancer appeared on December 26, 2014, when I was 32 years old. My family and I had just gotten home from celebrating the Christmas holiday with our relatives...
Combination of Nivolumab and Ipilimumab for Unresectable Malignant Pleural Mesothelioma
On October 2, 2020, the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) was approved for first-line treatment of adult patients with unresectable malignant pleural mesothelioma.1-3 Supporting Efficacy Data Approval was based on findings in the open-label phase III CheckMate 743 trial...
Beyond BROCADE3: Just the Beginning for Veliparib-Based Therapy in Advanced BRCA-Mutated Breast Cancer
As recently reported in The Lancet Oncology and reviewed in the October 10, 2020, issue of The ASCO Post, the phase III BROCADE3 trial has shown that the addition of veliparib to carboplatin and paclitaxel improved progression-free survival in previously treated BRCA-mutated advanced breast...
Expert Point of View: Kilian M. Gust, MD
Formal discussant Kilian M. Gust, MD, of the Medical University of Austria, Vienna, reminded listeners that JAVELIN Bladder 100 was designed at a time when no checkpoint inhibitor was approved for the treatment of metastatic urothelial cancer. In the past 5 years, five immune checkpoint inhibitors...
A Doctor Shares His Rich Life in Medicine and Cancer Research
“What am I doing here? This question kept running through my mind as the incoming freshman medical students at the University of Chicago assembled for the first time.” The person asking the introspective question was Marvin Stone, fresh out of college, recently married to his wife, Jill, and now a...
Front-Line Avelumab Maintenance Improved Survival Across Subgroups With Advanced Urothelial Carcinoma
A strategy of front-line maintenance treatment with the PD-L1 inhibitor avelumab combined with best supportive care improved both progression-free and overall survival vs best supportive care alone across prespecified subgroups of patients with advanced or metastatic urothelial carcinoma that had...
An Emergency Room Physician Explores Her Own Healing Through a Life of Medical Service
Medical memoir dramas, especially those centered in the emergency room (ER), are often met with the anticipation of top-rated medical shows portrayed on TV, in which there is nonstop blood-and-guts action and sizzling tensions between shouting doctors and nurses. In her recently published memoir,...
Dr. Christina Cone Honored With Mary Pazdur Award for Excellence in Advanced Practice in Oncology
The Advanced Practitioner Society for Hematology and Oncology (APSHO) presented the third annual Mary Pazdur Award for Excellence in Advanced Practice in Oncology to Christina Cone, DNP, APRN, ANP-BC, AOCNP, of Duke Cancer Institute, at this year’s JADPRO Live Virtual conference, an annual...
Predicting Cardiovascular Disease Risk Via Routine CT Scans in Women With Breast Cancer
Coronary artery calcification scores based on routine computed tomography (CT) scans used for planning radiotherapy therapy may be able to predict which women with breast cancer have a high probability of developing cardiovascular disease. The promise of this research is that once high-risk...
Expert Point of View: Charles L. Shapiro, MD
The ASCO Post asked Charles L. Shapiro, MD, Professor of Medicine, Director of Translational Breast Cancer Research, and Director of Cancer Survivorship at Icahn School of Medicine at Mount Sinai, New York, for his thoughts on the exploratory analysis of PALOMA-3. He first pointed out that the...
Using Meaning-Centered Interventions to Address Suffering on the Cancer Journey
A large body of research has shed light on how the cancer experience and related losses often leave patients and their families struggling to find a sense of meaning in their lives.1-7 The COVID-19 pandemic has amplified these difficulties, as meaningful activities and experiences have been...
ACCC Statement on Rise of Cancer Mortality and Advanced Cancer Rates in 2020
Randall A. Oyer, MD, President of the Association of Community Cancer Centers (ACCC), released a statement regarding the rise in mortality rates of specific cancers and the rise in the occurrence of advanced metastatic cancers in 2020. New research presented at the United European Gastroenterology ...
As a Young Oncologist, Enrique Soto Pérez de Celis, MD, MSc, Met a Career-Changing Mentor at the ASCO Annual Meeting
Geriatric oncologist and researcher Enrique Soto Pérez de Celis, MD, MSc, was born in Mexico City and grew up in the nearby city of Puebla. “There were no physicians in the family who might have influenced my decision to become a doctor, but both of my parents were academics; my mother was a...
OneOncology Launches Community Oncology Research Network
OneOncology, a partnership of independent oncology practices, has announced the formation of a separate subsidiary, the OneOncology Research Network (OneR). The new platform is a national nonexclusive clinical trial site management organization that will enhance the current research programs...
Pancreatic Adenocarcinoma: Leveraging Molecular Data to Drive Clinical Advances
With the worst 5-year overall survival of all cancers and the second-leading cause of cancer death, pancreatic adenocarcinoma remains a dismal prognosis for the vast majority of patients. However, more accurate tumor staging and better understanding of distinct molecular subgroups have started to...
Committed to Excellence: Oncology Drug Development Marches on Amid a Pandemic
Instituted as part of the 21st Century Cures Act, the Oncology Center of Excellence (OCE) fosters a unified interaction between three U.S. Food and Drug Administration (FDA) centers: Center for Biologics Evaluation and Research, Center for Drug Evaluation and Research, and Center for Devices and...
Liquid Biopsy: Mounting Evidence Shows Clinical Utility in Tumor Monitoring
A “blood-first” approach could soon shift the diagnostic paradigm in advanced lung cancer, replacing tissue biopsy with minimally invasive assays. According to Natasha B. Leighl, MD, MMSc, FRCPC, FASCO, there is rapidly mounting evidence that liquid biopsy serves a prognostic function in advanced...
Medical Financial Hardship: Pervasive and Possibly Linked to Mortality Among Patients With Cancer
Reducing the financial impact of cancer diagnosis and treatment may save not only bank accounts but lives as well, according to recent data. Two separate survey studies presented during the 2020 ASCO Quality Care Symposium have highlighted the pervasiveness and deadliness of financial toxicity,...
After Leaving His Home in Syria to Train Abroad, an Oncologist Makes a Tough Decision to Return
For this installment of the Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Nedal Estfan, MD, a noted Syrian oncologist who was at the forefront of his county’s earliest efforts to establish a national cancer care system during a time of political and military turmoil....
Chronic Lymphocytic Leukemia: New Treatments Achieve Deeper Remissions
At the National Comprehensive Cancer Network® (NCCN®) 2020 Virtual Congress: Hematologic Malignancies, William Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, Houston, reviewed current data on chronic lymphocytic leukemia (CLL), including promising new combinations of modern...
Do All Patients With Refractory Diffuse Large B-Cell Lymphoma Need CAR T-Cell Therapy?
Chimeric antigen receptor (CAR) T-cell therapy has made great strides in treating patients with relapsed or refractory diffuse large-B cell lymphoma (DLBCL) and refractory mantle cell lymphoma (MCL), but there may be newer strategies that can produce equivalent outcomes, and not all patients with...
Results From ASCO’s 2020 National Cancer Opinions Survey
As in past years, the results from ASCO’s 2020 National Cancer Opinions Survey showed a startling dichotomy in the perceptions of Americans on a variety of health-care issues. As expected, the two major events this year, the COVID-19 pandemic and a national reckoning over racial injustice,...
Lung Cancer: Precision Therapies at the Forefront
What a difference 20 years have made! In the year 2000, the results of the ECOG 1594 trial were reported at the plenary session of the ASCO Annual Meeting. The study demonstrated comparable outcomes between four different platinum-based chemotherapy regimens for the treatment of metastatic...
